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http://Contents lists available at ScienceDirectEditorialIs VEGF a new therapeutic target for hypertension in chronic
kidney disease?The prevalence of end-stage renal disease (ESRD) is more than
1,000 per million population in Korea, and is increasing by about
5% every year. The most common cause of ESRD is diabetes,
followed by hypertension and glomerulonephritis [1]. Hyperten-
sion, in particular, has been associated with 34% of all ESRDs in
African-Americans [2]. Various mechanisms have been suggested
to be involved in the development of hypertension, salt sensitivity
being one of the important derangements related to hypertension.
Total body sodium for homeostasis of the extracellular ﬂuid
volume is mainly regulated by the kidney [3]. Because extracel-
lular ﬂuid volume is controlled dynamically, excessive interstitial
sodium is readily moved into the intravascular ﬂuid for sodium
excretion via the kidney.
Along with the inﬂuence of hypertension, vascular remodel-
ing is closely related to the development and progression of
chronic kidney disease (CKD). In CKD, large arteries remodel and
become increasingly stiff. The greater pulse pressure reaching the
glomerulus as a result of the increased arterial stiffness could
induce renal damage, suggesting that the stiffening and remo-
deling of large arteries could affect the progression of CKD [4].
The maladaptive remodeling of the carotid artery and increased
pulse pressure are independently associated with a faster decline
of renal function and a faster progression to ESRD. In CKD, along
with the changes in the aorta and large arteries, the microcircu-
lation, consisting of small arteries and arterioles, capillaries, and
venules [5], is changed signiﬁcantly. In long-standing CKD, blood
vessels are characterized by calciﬁcations in both the intimal
and medial layers, leading to vascular stiffening and a loss of
compliance. As a result, both the pulsatile component of the
blood pressure, as indicated by an augmented pulse pressure,
and peripheral resistance, expressed as mean arterial pressure,
are increased [6]. In the microcirculation, these changes may
affect vasodilatory capacity, leading to a loss of capillary archi-
tecture and rarefaction [7]. Indeed, in patients with advanced
CKD, it has been reported that the functional and structural
number of capillaries is decreased [8].
In addition to CKD, aging is also associated with endothelial
dysfunction, resulting in a decreased vasodilatory response of
the microcirculation to a variety of stimuli [9]. Accelerated
vascular aging, associated with Klotho deﬁciency, is also a
characteristic of patients with CKD [10]. Even in childhood,
ESRD is associated with structural abnormalities in arterial
wall properties, comparable with adult levels [11].132/$ - see front matter & 2013. The Korean Society of Nephrology. Pub
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
dx.doi.org/10.1016/j.krcp.2013.04.008Vascular endothelial growth factor (VEGF) was discovered as a
factor capable of inducing endothelial cell permeability [12] and
angiogenesis [13]. So far, seven members of the VEGF family have
been identiﬁed: A, B, C, D, E, and placental growth factor 1 and 2.
VEGF mediates its effects through VEGF receptors (VEGFR-1,
VEGFR-2, and VEGFR-3), with VEGFR-2 as its primary cognate
receptor expressed on endothelial cells. As VEGF-targeted thera-
pies were introduced into clinical use for treatment of malignant
disease, it was noted that hypertension and proteinuria were
major toxicities of VEGF-targeted therapies. Hypertension occurs
in up to 80% of patients receiving VEGF, and most of the patients
taking these drugs reveal an elevation of blood pressure. Previous
studies evaluating bevacizumab showed a dose-dependent devel-
opment of hypertension [14]. Tyrosine kinase inhibitors such as
sorafenib and sunitinib are also associated with hypertension and
a pre-eclampsia-like syndrome [15].
At least two possible pathways for hypertension by VEGF-
targeted therapy have been suggested. First, nitric oxide has a
direct effect on the regulation of pressure natriuresis and tubu-
loglomerular feedback. VEGF inhibition may cause a disruption
of normal endothelial nitric oxide synthase function, and cause
sodium retention. Thus, extracellular ﬂuid volume increases by
changing the set point for sodium excretion [16].
In another pathway, a novel mechanism for VEGF-mediated
control of extracellular ﬂuid volume has been suggested.
In response to high salt loading, the production of VEGF-C by
macrophages increases, binding to VEGFR-3, and thus stimu-
lating lymphatic vessel growth. This lymphatic capillary net-
work is suggested to form a compartment that buffers the
extracellular ﬂuid volume in response to the increased sodium
intake, blunting the rise in blood pressure. Inhibition of VEGF-
C or macrophage depletion causes a decrease in lymphatic
vessel density, and increased blood pressure in response to a
high-salt diet [17].
VEGF-C is tightly associated with dyslipidemia, a potent risk
factor as well as a therapeutic target in cardiovascular disease. In
addition, it has been demonstrated that serum levels and expres-
sion levels of VEGF-C, but not VEGF-A, in atheromatous plaques
were signiﬁcantly increased in high-fat diet-fed apoE-deﬁcient
mice with advanced atherosclerosis, suggesting that VEGF-C was
more closely related than VEGF-A to atherosclerosis with dyslipi-
demia [18]. Therefore, VEGF-C might have more impact on
atherosclerosis and future cardiovascular events than VEGF-A inlished by Elsevier. This is an open access article under the CC BY-NC-ND
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of TonEBP in mononuclear phagocyte cells in the skin [17,19]. It
was suggested that TonEBP increases VEGF-C production and
increases lymphangiogenesis [20,21]. Therefore, VEGF-C can be a
regulated by a sodium-excessive state and activation of high
TonEBP in salt diet-induced hypertension.
In this issue of Kidney Research and Clinical Practice, Kim
et al. have evaluated the serum and urinary concentration of
VEGF-C in patients in various stages of CKD, including patients
on maintenance hemodialysis [22]. They hypothesized that the
change in serum VEGF-C would be associated with increasing
blood pressure. Compared with healthy controls, serum VEGF-
C levels were signiﬁcantly decreased in patients with CKD,
while the urinary excretion of VEGF-C was augmented in
CKD patients. In patients on hemodialysis, VEGF-C was also
decreased, but blood pressure did not directly reﬂect the
changes in VEGF-C concentration. Kim et al. assumed that
serum levels of VEGF-C might increase in hypertensive CKD
patients because VEGF-C is involved in salt-sensitive hyper-
tension, and hypertension in CKD patients may be linked to
volume expansion. However, they demonstrated that serum
levels of VEGF-C in CKD Stage 3–4 and Stage 5 hemodialysis
patients were signiﬁcantly lower than in controls. Therefore,
they concluded that extrarenal ﬂuid homeostasis occurring
via the VEGF-C system was less likely to be involved in CKD
patients with hypertension.
Although their ﬁndings are contradictory to the hypothesis,
which is based on the previous reports, the work done by Kim
et al. suggests a very interesting point, and may provide a new
concept of hypertension in CKD patients that has therapeutic
potential. First, if the serum level of VEGF-C is shown to be
consistently low in subsequent reports, the notion that the
premature vascular aging develops in CKD patients [22] is
plausible, and the association between premature vascular aging
and function of VEGF should be further investigated. The other
issue is the therapeutic potential of VEGF in blood pressure control
as well as the prevention of CKD progression. Augmentation of the
effect of VEGF in vivo may modulate salt metabolism, leading to
blood pressure control. If this hypothesis is consistently proven,
we might have another maneuver to control blood pressure. As a
start, we should have data that the individual antihypertensive
agents or classes affect, or at least correlate with, the in vivo
activity of various VEGFs. Renin–angiotensin system blockers and
calcium channel blockers are the main agents for evaluation here.
More importantly, if the modulation of VEGF is positively
associated with vascular remodeling in the ischemic tissue
(especially in the glomerulus or interstitium), this may provide
a new approach for preventing the progression of CKD.
Augmentation of the biologic effect of VEGFs in the damaged
tissue may show a new potential for tissue recovery or
regeneration. Further investigation should be exploited in the
near future.Conﬂict of Interest
Author does not have any conﬂict of interest.
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